Delcath Announces First CHEMOSAT Procedures ... ( NEW YORK Feb. 27 2012 /- Delcath Syst...)

Delcath Announces First CHEMOSAT Procedures in Germany

Date:2/27/2012

NEW YORK, Feb. 27, 2012 /PRNewswire/ -- Delcath Systems, Inc., (NASDAQ: DCTH) announced today that the first patients in Germany have been treated with the Delcath Hepatic CHEMOSAT^® Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the Company announced with the hospital in December 2011.

Two patients were treated for inoperable, liver-dominant metastases, one from cutaneous melanoma and one from breast cancer. The treating physicians reported that both patients were treated successfully without procedure-related complications.

Dr. Thomas J. Vogl, Director of the Institute for Diagnostic and Interventional Radiology at J.W. Goethe, said, "We believe this technology has significant potential to help control cancers in the liver. We're pleased to be the first cancer center to begin offering this important treatment option to patients in Germany, and are eager to further explore its role in the treatment of multiple tumor types including breast cancer."

"Delcath's partnership with J.W. Goethe reinforces the potential of CHEMOSAT," said Eamonn P. Hobbs, president and CEO of Delcath. "We recently treated our first patients in Milan and are eager to continue our expansion across Europe. Opening another CHEMOSAT treatment center and treating patients in the continent's largest market is another step forward in the commercialization of this technology."

About the Johann Wolfgang Goethe University Hospital

Founded in 1914, J.W. Goethe University Hospital is considered to be one of the leading university hospitals in Germany. Twenty-five research institutes working in close cooperation with the Medical Department bear witness to
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference

Post Your Comments:

(Date:5/21/2013)... WESTBURY, N.Y. , May 21, 2013 Vasomedical, Inc. ... specializing in the design, manufacture and sale of medical devices ... today that Dr. Jun Ma , President ... Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...

(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Technologies for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES ... study is to offer synopsis of the ...

(Date:5/21/2013)... Fla. , May 21, 2013 Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...

[0] Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference [0] Global Markets and Technologies for Optical Coherence Tomography (OCT)[0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients

... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) will ... Conference on Monday, September 20, 2010. The presentation is ... be accessed through the Company,s web site, www.regeneron.com ... of the presentation will be available after the live ...

... Shield Healthcare, a leading provider of medical supplies for ... annual story contest on "What Makes Caregiving Rewarding?" designed ... home healthcare professionals, featuring celebrity contest judge, Sandra Mitchell ... caregiving is a demanding job. A significant number of ...

Cached Medicine Technology:Shield Healthcare Announces 10th Annual Caregiver Story Contest 2

Regeneron Announces Presentation at the UBS Global Life Sciences Conference Shield Healthcare Announces 10th Annual Caregiver Story Contest

(Date:5/21/2013)... ROCHESTER, Minn. Positively charged gold nanoparticles are ... manage to avoid nanoparticle toxicity. Mayo Clinic researchers ... the nanoparticles effective against ovarian cancer cells. The ... of the Journal of Biological Chemistry ., ... ovarian cancer cells by preventing the cell death ...

(Date:5/21/2013)... Residents in St. Petersburg, FL have a ... Dr. David Sherberg, DMD, has joined Coast Dental Pasadena, ... provides preventive, restorative and cosmetic dentistry to patients age ... provide a wide variety of services including ... crowns, bridges, dentures, dental implant restorations, veneers, laser therapy, ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 TheBeautyPlace.com helps ... day. TheBeautyPlace.com features a Big Day Kit including all ... might need to shine on their Wedding Day. , ... to smile about on their Wedding Day. Flowers blooming ... the start of wedding season. From Memorial Day to ...

(Date:5/21/2013)... St. Louis, MO (PRWEB) May 21, 2013 ... the first insulin pump she used with her patients in the ... the “big blue brick.” For the most part, it could only ... greatly in the 30 years since then, and the advantages are ... device worn on the outside of the body, often on a ...

(Date:5/21/2013)... The producers of Net Worth Business TV ... Ontario, Canada. The area is famous for its natural beauty ... It is located an hour from Toronto and is easily ... the Kawartha Hills, home to several towns, villages and hamlets ... area. Residents and visitors to this region will be able ...

Breaking Medicine News(10 mins):Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2 Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 2 Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 3 Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 2 Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 3 Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 2 Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 3 Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 4 Health News:Net Worth Business TV Announces May Air Dates for Peterborough, Ontario 2

[0] Mayo Clinic: How gold nanoparticles can help fight ovarian cancer [0] Coast Dental Pasadena Welcomes Dr. David Sherberg [0] TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season [0] Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives [0] Net Worth Business TV Announces May Air Dates for Peterborough, Ontario

... Society, the largest non-government, not-for-profit funding source of cancer research ... training grants totaling more than $52.6 million in the first ... are new and 18 are renewals of previous grants. All ... The American Cancer Societys Research and Training Program has funded ...

... III development of ,GI-friendly, NSAIDs for mild ... Horizon Therapeutics, Inc. is pleased to announce that ... showcase Horizon,s ... including its recent completion of Series C financing, and ...

... Calcium Brand Enriches Consumer Care Division,s Key ... Nutritionals Product Portfolio, ... that its Consumer Care Division has received regulatory,approvals necessary to ... United States. The U.S. portion of the,transaction with Mission Pharmacal ...

... Oct. 5 Eli Lilly and Company,announced today ... the U.S. Food,and Drug Administration (FDA), the company ... fluoxetine HCl) U.S. product,labels. This new labeling information ... . The updates reflect recently completed pooled ...

... (CTI),(Nasdaq: CTIC ; MTAX) management will present at ... The conference will be held October 9-11, 2007, at ... Wednesday, October 10 at 12:45 p.m.,(PT). The conference will ... the presentation. The webcast can be accessed at, http://www.cticseattle.com ...

... SAN FRANCISCO, Calif., Oct. 5 Anesiva,Inc. (Nasdaq: ... company,s,chief executive officer, will present at the Biotechnology Industry,Organization,s ... am PDT in San Francisco. To access the ... http://www.anesiva.com and go to the Investors page, ...

Cached Medicine News:Health News:American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide 2 Health News:American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide 3 Health News:Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting 2 Health News:Bayer HealthCare Cleared to Acquire Citracal(R) 2 Health News:Bayer HealthCare Cleared to Acquire Citracal(R) 3 Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 2 Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 3 Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 4 Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 5 Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 6 Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 7 Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 8

American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting Bayer HealthCare Cleared to Acquire Citracal(R)Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum Anesiva to Present at BIO InvestorForum on October 11, 2007

The ImmunoWELL TPO IgG Quantitative Test is a quantitative enzyme immunoassay (EIA) for screening and detection of autoantibodies against human thyroid peroxidase (microsome) in serum and is used as ...

... The ImmunoDOT Autoimmunity Screening Panel 4 ... for screening and detection of autoantibodies ... (SS-A, SS-B, RNP/Sm, and Sm) in ... aid in the diagnosis of systemic ...

The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....

Rad-5 signal extraction pulse oximeter™...

Medicine Products:

ImmunoWELL TPO IgG Quantitative Test ImmunoDOT Autoimmunity Screening Panel 4 Pulse Oximeter Model: THS 8500 Rad-5 signal extraction pulse oximeter™